Mazdutide is an investigational peptide being studied for its potential use in treating obesity and type 2 diabetes. It is a dual incretin receptor agonist that targets both the GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) receptors. These receptors play a crucial role in regulating blood sugar levels, insulin secretion, and appetite. By activating both receptors, Mazdutide may help improve glycemic control, promote weight loss, and enhance metabolic health. Early studies suggest that Mazdutide could offer a more effective treatment option compared to existing therapies by providing a dual mechanism of action, potentially leading to better outcomes in weight management and diabetes control.